First Generics Of Eliquis Gets Approval Under FDA’s Generic Drug Program

The U.S. Food and Drug Administration has approved new medicines to minimize the chance of systemic embolism, nonvalvular atrial fibrillation, and stroke in the patients who are suffering from these disorders. The agency has announced two applications for the first generics of Eliquis (apixaban) tablets against stroke and systematic embolism.

The Eliquis tablets are designed to prevent the risk of deep vein thrombosis (DVT). A deep vein thrombosis is a severe form of pulmonary embolism (PE) in the patients who go through the replacement surgery of the hip or knee.

FDA is an agency that is linked with the Department of Health and Human Services, that is concerned to make effective biological drugs, vaccines and many medical devices for the safety of human. The FDA is also responsible for the protection of food supply, dietary products and to check the tobacco products.

Also read- New Study Shows Measuring Biomarkers of Inflammation May Diagnose Dementia At An Early Stage

The leading challenge that is addressed by the Food and Drug Administration is related to the improvement of generics to make it more advanced and to make the medicines of lower cost to make them affordable for the patients.

M.D. and Director of the FDA’s which is a center for Research and Drug Evaluation, Janet Woodcock, announces that apixaban tablets cost is low, the quality of these medicines is high and FDA’s generic drug program has worked to make the apixaban tablets of lower cost and high quality.

These tablets are safe to use and easy to purchase because of the lower cost. And the approval of the first generic apixaban tablets gives a trademark that idea of direct oral anticoagulant is acceptable and repeated blood testing cant done for direct oral anticoagulants. Direct oral anticoagulants are blood thinners.

Instructions are mentioned on the tablets box to provide guidelines to the patients, about the use of these drugs and the information of the safety drug is also mentioned there.

The Food and Drug Administration works especially for the patients when nonvalvular atrial fibrillation, deep vein thrombosis (DVT) and stroke reaches the danger level in them. Stroke forms blood clots in the blood that move towards the brain, that’s why it is a most serious concern because it leads to brain destruction. Atrial fibrillation also forms clots, a heart rhythm problem.

Also read- FDA approves new treatment for Migraines in adults

To prevent the patients from blood clotting, anti-clotting drugs or anticoagulants are recommended by the doctors. One of the Centers for Prevention and Disease Control has conducted a survey which shows that about 6.1 million people are suffering from atrial fibrillation in the U.S.

The patients should use apixaban until they show recovery from thrombosis. The patients who stop taking apixaban very early suffer a lot and the risks of thrombosis increased in them up to danger level. This increase may also cause a permanent or long term paralysis in them.

These risks also increased to a dangerous level when the apixaban is taken by those who have prosthetic heart valves and atrial fibrillation is caused in them due to heart valve. So, it’s necessary to make sure the cause of thrombosis before taking apixaban drugs.


Areeba Hussain

The author is a fulltime medical and healthcare writer. She graduated in Medical Microbiology and Immunology with distinction. Her areas of prime interest are medicine, medical technology, disease awareness, and research analysis. Twitter @Areeba94789300

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *


Adblock Detected

Please consider supporting us by disabling your ad blocker